TD Waterhouse Canada Inc. nearly exited its investment in Regeneron Pharmaceuticals, slashing its holdings by 98.8% in Q4, ...

Mumbai: Sanofi Consumer Healthcare India Ltd. has announced the company's Q1 results with Profit After Tax (PAT) at Rs 500 ...

Analysts anticipate Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.31. Anticipation surrounds Vertex Pharmaceuticals's announcement, with investors hoping to hear about both ...

MML Investors Services ramped up its Regeneron stake by 41.7%, acquiring 2,218 additional shares during Q4. This brings their ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

We recently published a list of Did Jim Cramer Nail All These 9 Stock Predictions?w. In this article, we are going to take a ...

Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

US Stock Market Live | Dow Jones | Nasdaq Today | Global markets surged after Trump ruled out firing Fed Chair Powell and ...

Investors are keenly awaiting corporate earnings from HCL Technologies, Axis Bank, and Maruti, alongside global tariff developments from the US, which are expected to influence market sentiment.

Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder.

Net interest margin was 4.41% in Q4-2025 compared to 4.25% in Q3-2025 and 4.40%in Q4-2024, the bank said in a filing. Provisions (excluding provision for tax) were higher at ₹891 crore in Q4 ...